Skip to main content
OpenTrials
Completed

NCT Number: NCT03189563

Safety and Efficacy of DA-9805 for Parkinson's Disease

This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects diagnosed with early Parkinson's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

30 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

HealthPartners Institute

Bloomington, Minnesota, 55425, United States

About this study

Parkinson's disease (PD) is recognized as one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years. There are 2 major neuropathologic findings: the loss of pigmented dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies.

Parkinson's disease affects an estimated 1.5 million persons in the United States, with over ten million affected worldwide, and these estimates are expected to increase substantially in the next few decades. Despite the increasing prevalence, the approved agents for the early management of Parkinson's disease have changed little in the past decade; however, there have been advances in drug delivery, dosing, and the use of combination therapy in an attempt to reduce adverse events. The most important, unmet medical need in targeting Parkinson's disease is developing agents with neuroprotective potential. So far, no drug has been shown to reduce or slow down the progression of PD.

DA-9805 is a botanical drug product composed of three main raw herbal materials. It is expected that DA-9805 will help treat PD by prevention of dopaminergic neurodegeneration via recovery of mitochondrial dysfunction, anti-inflammatory effect and relief from Endoplasmic reticulum (ER) stress and oxidative stress.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects who are between 30 and 79 years old inclusive with a clinical diagnosis of Parkinson's disease as per UK Brain Bank Criteria for two (2) years or less at screening.
  • Hoehn and Yahr I or II at screening.
  • Subjects who are newly diagnosed & currently not on any Parkinson's disease medication (or) subjects who are on stable doses for at least 4 weeks prior to screening on Amantadine or anticholinergics for treatment of Parkinson's disease

*Note: Subjects that had anti-parkinsonian medication (including levodopa, dopamine agonists, entacapone and monoamine oxidase-B inhibitors) discontinued at least 60 days prior to screening, e.g., for intolerance, may be considered eligible if all other eligibility requirements are met.

  • Women of child-bearing potential should use reliable contraception. Acceptable methods of contraception include: surgical sterilization (e.g. bilateral tubal ligation), hormonal contraception (implantable, patch, and oral), and double-barrier methods (condom, diaphragm and spermicide are each considered a barrier). Women of child-bearing potential are defined as women physiologically capable of becoming pregnant, UNLESS they meet the following criteria:

(1)Post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40mIU/m, OR; (2)6 weeks post surgical bilateral oophorectomy with or without hysterectomy

  • If a male and heterosexually active with a female of childbearing potential, the subject must agree to use a double barrier method of birth control (or must have been surgically sterilized) and to not donate sperm during the study.
  • Without clinically significant abnormalities in physical exam, neurological exam and laboratory assessments (urine/blood routine, biochemical tests and ECG) which would exclude the subject from the study in the opinion of the Investigator. For Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) the screening levels should be ≤ 2 times upper limit normal
  • Subject is capable of providing informed consent and is willing to sign the ICF prior to study Screening and agrees to comply with the study protocol requirements.

Exclusion criteria

  • Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease).
  • Subjects with history of neurosurgical intervention for Parkinson's disease.
  • Subjects who meet the DSM-V criteria at screening for bipolar disorder, major depressive disorder, psychotic disorders, or any other comorbid mental disorders that in the opinion of the Investigator may interfere with study conduct and results interpretation.
  • Subjects with clinical diagnosis of dementia (MMSE score <24) as determined by the investigator using Mini-Mental State Examination (MMSE).
  • Female subjects who are pregnant or breast feeding.
  • Initiation of any anti-parkinsonian medication (including levodopa, dopamine agonists, entacapone and monoamine oxidase-B inhibitors) for the duration of the trial.
  • Initiation of Amantadine or anticholinergics for newly diagnosed subjects or change in the dosage of Amantadine or anticholinergics during the trial for subjects who were on stable doses for 4 weeks prior to screening.
  • Subjects who used investigational drugs or devices within 60 days prior to screening or investigational biologics within the last 6 months prior to screening.
  • Subjects with a clinically significant or surgical condition, including major surgeries within 28 days prior to enrollment

Treatment and study plan

DA-9805 45mg

Drug

DA-9805 15mg tid

Other names: DA-9805

DA-9805 90mg

Drug

DA-9805 30mg tid

Other names: DA-9805

Placebo

Other

Placebo, tid

Primary outcomes

  1. Change in Motor MDS-UPDRS Score From Baseline at Week 12

    Time frame: 12 weeks

    Analysis of the Change from Baseline in the sum of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part II, Part III and Part IV at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) MDS-UPDRS is a multimodal scale assessing both impairment and disability and is separated into 4 subscales.

    Each parkinsonian sign or symptom is rated on a 5-point severity scale (ranging from 0 to 4).

    The maximum total UPDRS score is 272, indicating the worst possible disability from PD.

    Part I: This assesses non-motor experiences of daily living (13 items, Score range: 0~52) Part II: This assesses motor experiences of daily living (13 items, Score range: 0~52) Part III: This assesses the motor signs of PD (33 items, Score range: 0~132) Part IV: This assesses motor complications, dyskinesias and motor fluctuations using historical and objective information (6 items, Score range: 0~26)

Secondary outcomes

  1. Change in Total MDS- UPDRS Score

    Time frame: 12 weeks

    Analysis of the Change from Baseline in the sum of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part I, Part II, Part III and Part IV at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) MDS-UPDRS is a multimodal scale assessing both impairment and disability and is separated into 4 subscales.

    Each parkinsonian sign or symptom is rated on a 5-point severity scale (ranging from 0 to 4).

    The maximum total UPDRS score is 272, indicating the worst possible disability from PD.

    Part I: This assesses non-motor experiences of daily living (13 items, Score range: 0~52) Part II: This assesses motor experiences of daily living (13 items, Score range: 0~52) Part III: This assesses the motor signs of PD (33 items, Score range: 0~132) Part IV: This assesses motor complications, dyskinesias and motor fluctuations using historical and objective information (6 items, Score range: 0~26)

  2. Change in MDS-UPDRS Subscale scores_Part I

    Time frame: 12 weeks

    Analysis of the Change from Baseline in the sum of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part I at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) MDS-UPDRS is a multimodal scale assessing both impairment and disability and is separated into 4 subscales.

    Each parkinsonian sign or symptom is rated on a 5-point severity scale (ranging from 0 to 4).

    The maximum total UPDRS score is 272, indicating the worst possible disability from PD.

    Part I: This assesses non-motor experiences of daily living (13 items, Score range: 0~52) Part II: This assesses motor experiences of daily living (13 items, Score range: 0~52) Part III: This assesses the motor signs of PD (33 items, Score range: 0~132) Part IV: This assesses motor complications, dyskinesias and motor fluctuations using historical and objective information (6 items, Score range: 0~26)

  3. Change in S&E Total Score

    Time frame: 12 weeks

    Change in Schwab and England (S&E) Scale total score from baseline at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) The Schwab & England Activities of Daily Living (ADL) scale reflects the speed, ease, and independence with which an individual performs daily activities, or personal chores, such as eating, toileting, and dressing. This scale uses a rating scale from 0% to 100%, with 100% representing complete independence in performing daily activities and 0% representing a vegetative, bedridden state.

  4. Change in PDQ-39 Score- Summary Index

    Time frame: 12 weeks

    Change in Parkinson's Disease Questionnaire (PDQ-39) total score from baseline at week 12.(Change from baseline = Post Baseline Measurement - Baseline Measurement) The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility [10 items], activities of daily living [6 items], emotional wellbeing [6 items], stigma [4 items], cognition [4 items], social support [3 items], communication [3 items] and bodily discomfort [3 items]) which subjects consider to be adversely affected by the disease.

    Each item is scored on the following 5-point scale. The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are ass

  5. Change in H&Y Total Score at Week 12

    Time frame: 12 weeks

    Change in Hoehn and Yahr (H&Y) scale total score from baseline at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) H&Y describes five stages to PD progression (Score 1~5). A lower score represent a lower amount of symptoms.

  6. Change in MDS-UPDRS Subscale scores_Part II

    Time frame: 12 weeks

    Analysis of the Change from Baseline in the sum of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part II at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) MDS-UPDRS is a multimodal scale assessing both impairment and disability and is separated into 4 subscales.

    Each parkinsonian sign or symptom is rated on a 5-point severity scale (ranging from 0 to 4).

    The maximum total UPDRS score is 272, indicating the worst possible disability from PD.

    Part I: This assesses non-motor experiences of daily living (13 items, Score range: 0~52) Part II: This assesses motor experiences of daily living (13 items, Score range: 0~52) Part III: This assesses the motor signs of PD (33 items, Score range: 0~132) Part IV: This assesses motor complications, dyskinesias and motor fluctuations using historical and objective information (6 items, Score range: 0~26)

  7. Change in MDS-UPDRS Subscale scores_Part III

    Time frame: 12 weeks

    Analysis of the Change from Baseline in the sum of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) MDS-UPDRS is a multimodal scale assessing both impairment and disability and is separated into 4 subscales.

    Each parkinsonian sign or symptom is rated on a 5-point severity scale (ranging from 0 to 4).

    The maximum total UPDRS score is 272, indicating the worst possible disability from PD.

    Part I: This assesses non-motor experiences of daily living (13 items, Score range: 0~52) Part II: This assesses motor experiences of daily living (13 items, Score range: 0~52) Part III: This assesses the motor signs of PD (33 items, Score range: 0~132) Part IV: This assesses motor complications, dyskinesias and motor fluctuations using historical and objective information (6 items, Score range: 0~26)

  8. Change in MDS-UPDRS Subscale scores_Part IV

    Time frame: 12 weeks

    Analysis of the Change from Baseline in the sum of the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IV at week 12. (Change from baseline = Post Baseline Measurement - Baseline Measurement) MDS-UPDRS is a multimodal scale assessing both impairment and disability and is separated into 4 subscales.

    Each parkinsonian sign or symptom is rated on a 5-point severity scale (ranging from 0 to 4).

    The maximum total UPDRS score is 272, indicating the worst possible disability from PD.

    Part I: This assesses non-motor experiences of daily living (13 items, Score range: 0~52) Part II: This assesses motor experiences of daily living (13 items, Score range: 0~52) Part III: This assesses the motor signs of PD (33 items, Score range: 0~132) Part IV: This assesses motor complications, dyskinesias and motor fluctuations using historical and objective information (6 items, Score range: 0~26)

  9. Change in Clinical Global Impression-Severity (CGI-S)

    Time frame: 12 weeks

    The Global Impression-Severity (CGI) measures global severity of illness at a given point in time, and the improvement from baseline at visits following the initial baseline visit. (Change from baseline = Post Baseline Measurement - Baseline Measurement) At the screening and baseline visit, the investigator assessed the severity on a seven-point scale. At subsequent visits, the investigator was to assess the subject's severity (CGI-S) and improvement (CGI-I) relative to baseline.

    Severity of Illness (CGI-S) Rating should account for severity of the patient's illness. 0 = Not assessed

    • = Normal, not at all ill
    • = Borderline ill
    • = Mildly ill
    • = Moderately ill
    • = Markedly ill
    • = Severely ill
    • = Extremely ill

  10. Scores of Clinical Global Impression-Improvement (CGI-I)

    Time frame: 12 weeks

    The Global Impression-Severity (CGI) measures global severity of illness at a given point in time, and the improvement from baseline at visits following the initial baseline visit.

    At the screening and baseline visit, the investigator assessed the severity on a seven-point scale. At subsequent visits, the investigator was to assess the subject's severity (CGI-S) and improvement (CGI-I) relative to baseline.

    Global Improvement (CGI-I):

    Compared to the patient's condition at the baseline of this study, how much has the patient's illness improved or worsened? 0 = Not assessed

    • = Very much improved
    • = Much improved
    • = Minimally improved
    • = No change
    • = Minimally worse
    • = Much worse
    • = Very much worse

Sponsors and collaborators

Lead sponsor

Dong-A ST Co., Ltd.

Industry

Registry information

Official study title

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 16, 2017
Registry last updated
May 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.